company background image
DVA logo

DaVita NYSE:DVA Stock Report

Last Price

US$155.51

Market Cap

US$12.4b

7D

6.1%

1Y

19.7%

Updated

14 Apr, 2025

Data

Company Financials +

DaVita Inc.

NYSE:DVA Stock Report

Market Cap: US$12.4b

DVA Stock Overview

Provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. More details

DVA fundamental analysis
Snowflake Score
Valuation5/6
Future Growth0/6
Past Performance4/6
Financial Health3/6
Dividends0/6

Rewards

Trading at 46.4% below our estimate of its fair value

Earnings grew by 35.4% over the past year

Trading at good value compared to peers and industry

Risk Analysis

Earnings are forecast to decline by an average of 0.7% per year for the next 3 years

Has a high level of debt


DaVita Inc. Competitors

Chemed

NYSE:CHE

US$8.7b

Labcorp Holdings

NYSE:LH

US$18.5b

Quest Diagnostics

NYSE:DGX

US$18.2b

CorVel

NasdaqGS:CRVL

US$6.0b

Price History & Performance

Summary of share price highs, lows and changes for DaVita
Historical stock prices
Current Share PriceUS$155.51
52 Week HighUS$179.60
52 Week LowUS$125.64
Beta1.04
1 Month Change8.41%
3 Month Change-4.01%
1 Year Change19.66%
3 Year Change30.11%
5 Year Change100.61%
Change since IPO3,716.18%

Recent News & Updates

Returns On Capital At DaVita (NYSE:DVA) Have Stalled

Apr 02
Returns On Capital At DaVita (NYSE:DVA) Have Stalled

We Ran A Stock Scan For Earnings Growth And DaVita (NYSE:DVA) Passed With Ease

Mar 20
We Ran A Stock Scan For Earnings Growth And DaVita (NYSE:DVA) Passed With Ease

The DaVita Dilemma: Flat Patient Enrollment And Lawsuits, Yet An Improvement In Net Income Margin

Mar 17

Is Now An Opportune Moment To Examine DaVita Inc. (NYSE:DVA)?

Mar 07
Is Now An Opportune Moment To Examine DaVita Inc. (NYSE:DVA)?

Recent updates

Returns On Capital At DaVita (NYSE:DVA) Have Stalled

Apr 02
Returns On Capital At DaVita (NYSE:DVA) Have Stalled

We Ran A Stock Scan For Earnings Growth And DaVita (NYSE:DVA) Passed With Ease

Mar 20
We Ran A Stock Scan For Earnings Growth And DaVita (NYSE:DVA) Passed With Ease

The DaVita Dilemma: Flat Patient Enrollment And Lawsuits, Yet An Improvement In Net Income Margin

Mar 17

Is Now An Opportune Moment To Examine DaVita Inc. (NYSE:DVA)?

Mar 07
Is Now An Opportune Moment To Examine DaVita Inc. (NYSE:DVA)?

DaVita: Momentum Could Fade Given High Valuation

Feb 05

Does DaVita (NYSE:DVA) Have A Healthy Balance Sheet?

Jan 30
Does DaVita (NYSE:DVA) Have A Healthy Balance Sheet?

Market Still Lacking Some Conviction On DaVita Inc. (NYSE:DVA)

Dec 15
Market Still Lacking Some Conviction On DaVita Inc. (NYSE:DVA)

DaVita's (NYSE:DVA) Returns On Capital Are Heading Higher

Nov 30
DaVita's (NYSE:DVA) Returns On Capital Are Heading Higher

DaVita: Better Results Than Fresenius, But A 'Hold' Due To Valuation

Nov 14

Is DaVita Inc. (NYSE:DVA) Potentially Undervalued?

Nov 13
Is DaVita Inc. (NYSE:DVA) Potentially Undervalued?

Is DaVita (NYSE:DVA) A Risky Investment?

Oct 29
Is DaVita (NYSE:DVA) A Risky Investment?

An Intrinsic Calculation For DaVita Inc. (NYSE:DVA) Suggests It's 47% Undervalued

Sep 16
An Intrinsic Calculation For DaVita Inc. (NYSE:DVA) Suggests It's 47% Undervalued

DaVita Inc.'s (NYSE:DVA) Shares Lagging The Market But So Is The Business

Sep 01
DaVita Inc.'s (NYSE:DVA) Shares Lagging The Market But So Is The Business
author-image

Critical Investments And Policy Changes Propel Healthcare Innovator Towards Brighter Financial Horizons

Aug 22 DaVita's investments in technology and workforce initiatives aim to enhance revenue operations and patient care, contributing to future growth and profitability.

DaVita (NYSE:DVA) Has A Pretty Healthy Balance Sheet

Jul 02
DaVita (NYSE:DVA) Has A Pretty Healthy Balance Sheet

Is There Now An Opportunity In DaVita Inc. (NYSE:DVA)?

Jun 19
Is There Now An Opportunity In DaVita Inc. (NYSE:DVA)?

Are DaVita Inc. (NYSE:DVA) Investors Paying Above The Intrinsic Value?

Jun 04
Are DaVita Inc. (NYSE:DVA) Investors Paying Above The Intrinsic Value?

Returns On Capital At DaVita (NYSE:DVA) Have Hit The Brakes

May 22
Returns On Capital At DaVita (NYSE:DVA) Have Hit The Brakes

DaVita Stock Is A Hold As It Expands In Latin America

Mar 18

DaVita: Assessing After The Rally

Dec 29

DaVita: Simple And Compelling After Sell-Off

Oct 26

DaVita: Continued Economic Hurdles, Market Expectations May Be Correct

Oct 05

DaVita: Breakout Not Supported Without Leverage Effects, Reiterate Hold

Jul 21

Shareholder Returns

DVAUS HealthcareUS Market
7D6.1%9.3%5.8%
1Y19.7%12.9%4.8%

Return vs Industry: DVA exceeded the US Healthcare industry which returned 13.6% over the past year.

Return vs Market: DVA exceeded the US Market which returned 3.6% over the past year.

Price Volatility

Is DVA's price volatile compared to industry and market?
DVA volatility
DVA Average Weekly Movement5.5%
Healthcare Industry Average Movement7.4%
Market Average Movement7.7%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market4.1%

Stable Share Price: DVA has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: DVA's weekly volatility (6%) has been stable over the past year.

Community vs My Fair Value

Select a narrative for quick price alerts from the community, or create your own.

DVA logo
DaVita
AN
AnalystConsensusTarget
Consensus Narrative from 9 Analysts

Kidney Smart And IKC Programs Will Deliver Holistic Kidney Care In Partnership With CMS

Key Takeaways DaVita's expansion into comprehensive kidney care and international markets is strategically positioning the company for future revenue and earnings growth. Focus on enhancing collection performance and share repurchase strategy aims to improve net margins and achieve strong earnings per share growth.
View narrative
US$164.57
FV
5.5% undervalued intrinsic discount
4.24%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
16users have followed this narrative
4 days ago author updated this narrative
View DaVita Community

About the Company

FoundedEmployeesCEOWebsite
199476,000Javier Rodriguezwww.davita.com

DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.

DaVita Inc. Fundamentals Summary

How do DaVita's earnings and revenue compare to its market cap?
DVA fundamental statistics
Market capUS$12.44b
Earnings (TTM)US$936.34m
Revenue (TTM)US$12.82b

13.3x

P/E Ratio

1.0x

P/S Ratio

Is DVA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
DVA income statement (TTM)
RevenueUS$12.82b
Cost of RevenueUS$8.60b
Gross ProfitUS$4.22b
Other ExpensesUS$3.28b
EarningsUS$936.34m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)11.70
Gross Margin32.91%
Net Profit Margin7.31%
Debt/Equity Ratio441.4%

How did DVA perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/04/14 04:50
End of Day Share Price 2025/04/11 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

DaVita Inc. is covered by 35 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Stephan GasteygerAtlantic Equities LLP
Brian WilliamsAvondale Partners
Matthew GillmorBaird